Cornerstone Planning Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Cornerstone Planning Group’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.52K	Hold	42	–	–	﹤0.01%	1181
2026 Q1	$1.71K	Hold	42	–	–	﹤0.01%	1329
2025 Q4	$2.15K	Hold	42	–	–	﹤0.01%	1179
2025 Q3	$1.82K	Buy	42 +38	+950%	+$1.22K	﹤0.01%	1182
2025 Q2	$117	Hold	4	–	–	﹤0.01%	1485
2025 Q1	$129	Hold	4	–	–	﹤0.01%	1489
2024 Q4	$153	Hold	4	–	–	﹤0.01%	1337
2024 Q3	$225	Hold	4	–	–	﹤0.01%	1224
2024 Q2	$197	Hold	4	–	–	﹤0.01%	1178
2024 Q1	$189	Hold	4	–	–	﹤0.01%	1017
2023 Q4	$142	Hold	4	–	–	﹤0.01%	881
2023 Q3	$119	Buy	+4	New	+$82	﹤0.01%	1079

Other funds holding CRNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

BSA

Braun Stacey Associates New York $3.53B AUM 63.32% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Cornerstone Planning Group's CRNX Position: Q2 2026 in Review

Cornerstone Planning Group held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 42 shares worth $3.52K. The position accounts for ﹤0.01% of the portfolio, ranked #1181.

Cornerstone Planning Group first reported a position in CRNX in Q3 2023 and has held it in 12 quarters since. 110 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Cornerstone Planning Group held 42 shares of Crinetics Pharmaceuticals worth $3.52K as of Q2 2026.
Cornerstone Planning Group left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
Crinetics Pharmaceuticals made up ﹤0.01% of Cornerstone Planning Group's portfolio in Q2 2026, its #1181 holding.
Cornerstone Planning Group first reported a position in Crinetics Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
110 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Cornerstone Planning Group's 13F filing for Q2 2026, filed 29 Jul 2026.